No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Owen Mumford Achieves B Corp Certification

Editor: What To Know

  • Owen Mumford, which established its sustainability program in 2014 and has formally committed to the UN's Sustainable Development Goals (SDGs), now joins a highly respected community of for-profit businesses that are applying growth and profit to the positive gain of the environment and external communities, as well as employees.
  • Owen Mumford has pioneered the design and manufacture of medical devices such as self-injection, blood sampling, and drug delivery for almost 70 years and is the first such company to become part of the B Corp community.
  • B Corp provides a solid benchmark for continually improving what we do in our business, in the global communities that we are part of and the ones where can make a positive impact.

Owen Mumford, a global leader in the design, manufacture, and advancement of medical devices, today announced it has been awarded B Corp certification after demonstrating strict compliance to the rigorous requirements of this hard-to-achieve, globally-recognized mark.

Owen Mumford, which established its sustainability program in 2014 and has formally committed to the UN’s Sustainable Development Goals (SDGs), now joins a highly respected community of for-profit businesses that are applying growth and profit to the positive gain of the environment and external communities, as well as employees.

B Corp is the standard for a new generation of aspirational brands who are helping to define the future of business in a responsible way. There are now 4,010 B Corps in 77 countries and 153 industries, and over 100,000 companies manage their impact with the B Impact Assessment and the SDG Action Manager. The B Corp community in the UK, representing a broad cross-section of industries and sizes, comprises over 400 companies.

B Corp certification assesses five areas of impact: governance, community, workers, environment and customers. “Our social and environmental responsibilities have always been high on the agenda at Owen Mumford,” said Jarl Severn, CEO at Owen Mumford. “Submitting ourselves to the rigorous process of B Corp certification is a natural development of our core principles. Companies like ours that operate in the medical sector are used to the demands of a tightly regulated environment. We believe that it is not enough simply to state ethical and environmental aspirations, but it is also critical to achieving a recognized certification. After all, our marketplaces are reliant on top ethical standards to protect environments, professionals and patients. B Corp provides a solid benchmark for continually improving what we do in our business, in the global communities that we are part of and the ones where can make a positive impact.”

Owen Mumford has pioneered the design and manufacture of medical devices such as self-injection, blood sampling, and drug delivery for almost 70 years and is the first such company to become part of the B Corp community. This milestone firmly underscores its commitment to making a positive difference on social and environmental impact.

Kate Sandle, Director of Programmes and Engagement of B Lab UK, says “We are delighted to welcome Owen Mumford to the B Corp community. This is a movement of companies who are committed to changing how the business operates and believe business really can be a force for good. We know that Owen Mumford is going to be a fantastic addition to the community and will continue driving the conversation forward. Welcoming Owen Mumford is an exciting moment because it has an opportunity to lead the way within the medical device industry.”

B Corp certification must be renewed every three years to ensure continuing compliance to the stringent requirements.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy